Letter To The Editor
1 Demers Consulting Services Carmel CA, 93923
The AAP statement entitled "Reassessment of the Indications for Ribavirin Therapy in Respiratory Syncytial Virus Infections" by the Committee on Infectious Diseases1 recently published in this journal was noted with interest. It is extremely unfortunate that the Committee placed so little credence in the Stanford study published in the New England Journal of Medicine in 1991,2 while placing excessive confidence in the fatally flawed Wayne State study published in Critical Care Medicine in 1994.3 The Stanford study, among others, was criticized because ". . . the choice of water as a placebo . . . could have biased the results in favor of ribavirin efficacy."1




